The femoral artery has been the traditional approach for implantation of the Impella left ventricular assist device. We describe the case of a young man with toxic (cocaine-related) cardiomyopathy, severe left ventricular dysfunction, and moderate mitral insufficiency who received a transfemoral Impella left ventricular assist device that was relocated to the right axillary artery due to uncontrolled femoral access bleeding. The patient immediately stabilized post-implantation and was successfully bridged to a full recovery 6 days later.
SeyfarthMSibbingDBauerI. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol2008; 52: 1584–1588.
2.
LamarcheYCheungAIgnaszewskiA. Comparative outcomes in cardiogenic shock patients managed with Impella microaxial pump or extracorporeal life support. J Thorac Cardiovasc Surg2011; 142: 60–65.
3.
CatenaEMilazzoFMerliM. Echocardiographic evaluation of patients receiving a new left ventricular assist device: the Impella Recover 100. Eur J Echocardiogr2004; 5: 430–437.
4.
ConradSARycusPTDaltonH. Extracorporeal Life Support Registry Report 2004. ASAIO J2005; 51: 4–10.
5.
SassardTScalabreABonnefoyESanchezIFarhatFJegadenO. The right axillary artery approach for the Impella Recover LP 5.0 microaxial pump. Ann Thorac Surg2008; 85: 1468–1470.
6.
SabikJNemehHLytleB. Cannulation of the axillary artery with a side graft reduces morbidity. Ann Thorac Surg2004; 77: 1315–1320.
7.
OsesPCasassusFLerouxLCalderonJBarandonL. Optimization of Impella 5.0 implantation using mini-sternotomy approach in postmyocardial infarction cardiogenic shock. J Card Surg2012; 27: 605–606.
